Compare MPB & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | OMER |
|---|---|---|
| Founded | 1868 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 844.6M |
| IPO Year | 1996 | 2008 |
| Metric | MPB | OMER |
|---|---|---|
| Price | $37.24 | $13.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $37.00 | $32.50 |
| AVG Volume (30 Days) | 153.4K | ★ 1.4M |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ 1.22 | 0.62 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | $233.22 |
| P/E Ratio | $30.82 | ★ $21.37 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.56 | $3.94 |
| 52 Week High | $39.15 | $17.65 |
| Indicator | MPB | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 70.75 |
| Support Level | $30.82 | $10.82 |
| Resistance Level | $37.18 | $15.32 |
| Average True Range (ATR) | 0.90 | 0.66 |
| MACD | -0.11 | 0.28 |
| Stochastic Oscillator | 55.16 | 98.78 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.